How Biocon Biologics is taking on the US biosimilars market
Biocon Biologics is betting big that it can be a top US biosimilars company.
With its $3 billion acquisition of Viatris’ biosimilar portfolio last November now fully integrated, Biocon is readying a more concerted commercial push.
It’s up against some 800-pound gorillas — the established and marketing-savvy Big Pharma biosimilar companies like Amgen, Novartis, Pfizer and Biogen. But Biocon isn’t new to marketing biosimilars in the US, thanks to its 10-year partnership with Viatris. Together, they launched the first biosimilar to Amgen’s Neulasta, Fulphila (pegfilgrastim), in 2018, followed by the first biosimilar rival to Genentech blockbuster Herceptin, called Ogivri (trastuzumab) in 2019.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.